NATCAPSUQ Natural Capsules Q4 FY26 results (Jan–Mar 2026) and concall
Natural Capsules reported a mixed Q4 and FY26, with Q4 showing a significant sequential recovery in revenue and EBITDA, driven by cleared deferred capsule dispatches. However, the full year saw a consolidated net loss of Rs. 24.66 crores, primarily due to operational disruptions in the capsule business and pre-commercial costs of the API subsidiary. The company is focused on leveraging new HPMC capacity, scaling API sales, and formalizing the Fermbox collaboration to drive profitability in FY27, while addressing liquidity challenges through potential fundraising.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 14.5%, net profit up 109.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 41 | 43 | 44 | 44 | 45 +9% | 34 −21% | 51 +15% |
| EBITDA | 5 | 5 | 5 | 5 | 5 +10% | 2 −59% | 9 +76% |
| Net profit | 1 | 2 | 3 | 3 | 3 +205% | 0 −79% | 6 +110% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
